Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
Luye Pharma's Schizophrenia Injectable Surpasses Patent Challenges in US; Shares Fall 3%
綠葉製藥的精神分裂症注射劑超過了美國的專利挑戰;股價下跌了3%
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊